No Data
UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment
uniQure (QURE) shares rose 8% in recent Monday trading after the company obtained the regenerative medicine advanced therapy designation from the US Food and Drug Administration for AMT-130 to treat H
UniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's disease ~ ~ Receiving
UniQure N.V. (NASDAQ:QURE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for uniQure N.V. (NASDAQ:QURE) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.5% to US$4.89. Revenues of US$8.5m
Stifel Nicolaus Sticks to Its Buy Rating for UniQure (QURE)
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target